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Prominent members of the human gut microbiota
express endo-acting O-glycanases to initiate mucin
breakdown
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Christopher A. Lamb 4, Christopher J. Stewart5, Katie Cooke5, Mary Doona4, Stephanie Needham6,
Richard R. Brady7, Janet E. Berrington8, Katarina Madunic 9, Manfred Wuhrer 9, Peter Chater1,
Jeffery P. Pearson1, Robert Glowacki10, Eric C. Martens 10, Fuming Zhang11, Robert J. Linhardt 11,
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The thick mucus layer of the gut provides a barrier to infiltration of the underlying epithelia by
both the normal microbiota and enteric pathogens. Some members of the microbiota utilise
mucin glycoproteins as a nutrient source, but a detailed understanding of the mechanisms
used to breakdown these complex macromolecules is lacking. Here we describe the discovery
and characterisation of endo-acting enzymes from prominent mucin-degrading bacteria that
target the polyLacNAc structures within oligosaccharide side chains of both animal and
human mucins. These O-glycanases are part of the large and diverse glycoside hydrolase 16
(GH16) family and are often lipoproteins, indicating that they are surface located and thus
likely involved in the initial step in mucin breakdown. These data provide a significant advance
in our knowledge of the mechanism of mucin breakdown by the normal microbiota. Fur-
thermore, we also demonstrate the potential use of these enzymes as tools to explore
changes in O-glycan structure in a number of intestinal disease states.
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The human gastrointestinal (GI) tract is home to a large andcomplex community of microbes known as the human gutmicrobiota (HGM), with the greatest densities assembling
in the large intestine were numbers of bacterial cells are estimated
to be ~100 trillion1. The mucus layer shields the host epithelial
cells of the GI tract from both the normal microbiota and enteric
pathogens. Mucus is predominantly composed of gel-forming
mucins, which are complex glycoproteins secreted by the epi-
thelial cells2. Different mucin genes are expressed in different
mucosal surfaces throughout the body and mucins are at least
50% O-glycan by mass3. In the colon, MUC2 is the most abun-
dant gel-forming mucin and is composed of ~80% glycan1. While
the number of different monosaccharides and types of sulphate
decoration making up mucin oligosaccharide side chains are
relatively limited, the order in which they can be assembled is
hugely variable (Fig. 1a). The heterogeneity between individual
O-glycan chains leads to a highly complex macromolecule and it
is this complexity that provides some resistance to microbial
degradation and contributes to the mucus layers’ protective role4.
Despite this heterogeneity, some prominent bacterial members of
the microbiota have developed the capacity to graze on mucins,
including certain Bacteroides spp. and Akkermanisa mucini-
phila5–9. This ability is thought to be critical to the initial colo-
nisation by the microbiota in a new-born and therefore to the
development of a healthy adult microbiota10. Mucin grazing also
enables survival during the absence of diet-derived glycans11 and
non-mucin degrading species have been shown to be cross-fed by
mucin degraders, contributing to the long-term survival and
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Fig. 1 Mucin structure and genomic context of the loci encoding the mucin-associated GH16 enzymes. a Left: the main structural features of a model
mucin O-glycan chain. All mucin oligosaccharides are linked via an α-GalNAc to serine and threonine residues in the peptide backbone. A number of
different core structures are then attached, with core 3 (shown) being the most common in the large intestinal MUC2. The cores are then often extended
with polyLacNAc repeats of varying lengths which are decorated along their length by sulfation and fucosylation and capped at the non-reducing end by a
variety of α-linked monosaccharides. Right: a model of an intestinal mucin glycoprotein showing complexity and variability of glycan chains attached to
peptide backbone. b Genetic context of the GH16 encoding genes identified as being upregulated in the four species shown during growth on mucin (see
Supplementary Figs. 1–3). In Bacteroides spp. the GH16 genes (highlighted red) are part of discrete polysaccharide utilisation loci (PULs), cluster of co-
regulated genes encoding glycan degradation and uptake apparatus (SusC-like and SusD-like outer membrane proteins, additional CAZymes and putative
surface glycan binding proteins (pSGBPs), often adjacent to a hybrid two component system (HTCS) sensor-regulators that likely control expression of the
associated PUL. Glycan utilisation genes are not organised into PULs in the A. muciniphila genome.
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stability of the microbiota12,13. In contrast, aberrant or excess
degradation of the mucosal layer by the normal microbiota has
been linked to enhanced pathogen susceptibility, inflammatory
bowel disease (IBD) and even colorectal cancer11,14.
Despite the importance to gut health of mucin breakdown by
the microbiota, little is known about the molecular details of this
process. Current models of mucin degradation propose extra-
cellular sequential trimming of terminal sugars from the O-glycan
side chains by extracellular exo-acting glycosidases to eventually
expose the peptide backbone for proteolysis15. However, this
extracellular ‘exo-trimming’ model is based only on the activity of
currently characterised mucin active enzymes, such as sialidases
and fucosidases. The exo-trimming model is also in direct con-
trast with the degradation pathways used by Gram-negative
Bacteroidetes, known as the Sus paradigm16. Sus-like systems
derive their name (Starch utilisation system) after the first such
system characterised, but each Sus-like apparatus targets a dis-
tinct glycan, and many Bacteroides spp. contain tens to hundreds
of these systems. In general, in Sus-like systems, a surface endo-
acting glycanase cleaves the substrate (polysaccharide or glyco-
conjugate) into smaller oligosaccharides for uptake by SusC/D
outer membrane complexes17–19.
Here we describe the discovery and characterisation of endo-
acting glycoside hydrolases expressed by mucin-degrading
members of the HGM that are able to cleave the O-glycan
chains of a range of different animal and human mucins. These
O-glycanases display endo-β1,4-galactosidase activity and speci-
fically target the polyLacNAc structures that comprise the main
backbone of many mucin glycan chains. Furthermore, many of
the enzymes are predicted to be surface located and thus support
a model where the initial steps of mucin degradation by gut
bacteria involves the extracellular removal of oligosaccharides
from the glycoprotein. We also provide evidence these endo O-
glycanases could be exploited as tools to explore the composition
of human O-glycans from a range of different sources, with
potential applications in both basic research and precision
medicine.
Results
Identification of GH16 enzymes expressed during growth on
mucin. The foundation to this work was the analysis of pre-
viously published transcriptomic and proteomic data available
from four prominent mucin degrading HGM species (Bacteroides
thetaiotaomicron, B. fragilis, B. caccae and A. muciniphila) grown
on intestinal mucins8,11,20–23. The genes and proteins highlighted
in these studies included many putative exo-acting enzymes from
CAZy families (carbohydrate active enzymes; CAZymes) that
have previously been identified as involved degradation of O-
glycans, such as sialidases (GH33) and fucosidases (GH29 and
GH95; Supplementary Figs. 1–3). Surprisingly, some of the most
upregulated CAZymes in all species analysed were from glycoside
hydrolase family 16 (GH16). This was unexpected as GH16
enzymes have been predominantly characterised as targeting a
variety of marine or terrestrial plant polysaccharides, specifically
β1,3 or 1,4 glycosidic bonds of glucans and galactans almost
exclusively in an endo-acting fashion (Supplementary Fig. 4). For
Bacteroides species belonging to the HGM, the GH16 enzymes
that have been characterised so far include specificities towards
porphyran, agarose, β-1,3-glucan, and mixed linkage glucan24–27.
The genetic loci encoding the GH16 enzymes upregulated on
mucin also contain genes encoding SusCD pairs for the Bacter-
oides spp. and, in the case of B. fragilis, other predicted CAZymes
(Fig. 1b). The CAZymes encoded in the A. muciniphila genome
are not organised into loci. The modular structure of the mucin-
associated GH16 enzymes are shown (Fig. 2).
Specifically, the GH16 enzymes identified are a part of
subfamily 3, which is a large and sequence-diverse subfamily
characterised predominantly as β1,3/4-glucosidases found in
Metazoa, Fungi, Archaea and Bacteria28. A total of nine GH16
enzymes were identified from the four species (Figs. 1b, 2, and
Supplementary Figs. 1–3). Five of the nine GH16 enzymes are
predicted lipoproteins and therefore likely cell surface associated
(Supplementary Table 1). Interestingly, these GH16 family
members generally had a relatively low sequence identity between
24–34%. The exceptions to this were two pairs of B. fragilis and B.
caccae enzymes: BF4058 and BACCAC_02679 and BF4060 and
BACCAC_02680 with 87 and 79% identity, respectively (Fig. 2
and Supplementary Table 2).
Phylogenetic analysis of mucin-associated GH16 enzymes. The
protein sequences of the nine GH16 family members identified as
upregulated during growth on mucins were compared with the
characterised GH16 family members from the CAZy database
(Supplementary Fig. 5 and Supplementary Table 3). The phylo-
genetic tree indicates that the mucin-associated GH16 enzymes
are most closely related to the β-glucanase GH16 family members
rather than those with activities on β-galactans, xyloglucan or
chitin- β1,6-gluconotransferases. Another analysis of the
GH16 subfamily 3 protein sequences indicate that seven of the
mucin-associated GH16 enzymes cluster together (Supplemen-
tary Fig. 6). The branch where they sit is composed of proteins
only from mucosal-associated organisms, including known
pathogens. Two of the A. muciniphila enzymes (Amuc_0724 and
Amuc_0875) cluster in a different branch and are relatively close
to GH16 family members that have been characterised as having
endo β-1,3-galactanase activity (Supplementary Fig. 6). The two
separate clusters indicate that the mucin-associated GH16
enzymes have evolved twice from different β-glucanase ancestors
(Supplementary Fig. 6). The enzymes that cluster with these
sequences potentially have similar activities. While the mucin-
associated GH16 enzymes are present in prominent mucin
degrading Gram-negative bacteria such as Bacteroides spp.,
inspection of the genomes of mucin-degrading Gram positive
members of the gut microbiota, including some Ruminococcus
and Bifidobacteria spp., revealed no evidence for these enzymes29.
The mucin-associated GH16 genes encode endo-acting O-gly-
canases. To explore the activity of the nine mucin-upregulated
GH16 family members, the recombinant forms of the enzymes
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Fig. 2 Domain structure of the mucin-associated GH16 enzymes
characterised in this study. GH16 catalytic domain (green), Type I signal
peptide (light blue), Type II signal peptide (orange). BT2824 also has an N-
terminal DUF4971 domain (PF16341) of unknown function. Sequence
identity is between 22 and 38% for most of the enzymes, but two pairs of
the GH16 enzymes are close homologues - BF4058 and BACCAC_02679
(red asterisk) display 87% identity, while BF4060 and BACCAC_02680
(black asterisk) display 79% identity.
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were screened against porcine small intestinal (SI) mucin and
porcine gastric mucins (PGM type II and III; Supplementary
Fig. 7). Initial analysis by thin layer chromatography (TLC)
suggested that all nine enzymes were active against both SI and
gastric mucins and released a range of products from these gly-
coproteins that are larger than monosaccharides, suggesting
endo-like cleavage of the O-glycan chains.
To investigate the identity of these products in more detail, the
glycans were labelled at their reducing end with the fluorophore
procainamide and analysed by liquid chromatography-fluores-
cence-detection-electrospray-mass spectrometry (LC-FLD-ESI-
MS) and the glycan structures determined by MS/MS (Fig. 3).
The data show that all the GH16 enzymes produce oligosacchar-
ides of alternating hexose and HexNAc sugars with a variety of
lengths. The reducing ends were all hexoses, indicating hydrolysis
occurred at β-galactose (α-galactose only occurs in mucins as a
terminal sugar in blood group B structures and GH16 enzymes
only target β-linked sugars) and the products also had a range of
fucose and sulphate decorations, revealing these can be
accommodated by the GH16 enzymes. Overall, these data
indicate that the nine GH16 enzymes are all endo-acting β-
galactosidases that are active on the O-glycan side chains of
mucin (O-glycanases).
Notably, sialic acid (SA) was never observed as a decoration on
any products released by the enzymes, even though SA is present
on mucin glycans (Fig. 3). These data suggest this terminal sugar
decoration cannot be accommodated by the GH16 O-glycanases
and, as a result, the broad acting sialidase BT0455GH33 was
included in all assays to maximise access of the GH16 enzymes to
the mucin chains.
To investigate the composition of the oligosaccharides that are
released by the GH16 O-glycanases in greater detail we digested
the GH16 products with a series of exo-acting glycosidases of
known specificity. For example, digestion with glycosidases
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Fig. 3 Activity of the GH16 O-glycanases against porcine small intestinal mucin. SI mucin was incubated with the GH16 enzymes alongside a broad-
acting sialidase (BT0455GH33). The control is sialidase-only. Products of small intestinal mucin digestion were labelled with procainamide at the reducing
end and analysed by LC-FLD-ESI-MS. The results show a variety of oligosaccharides are released by the GH16 enzymes and majority are similar between
the samples. The oligosaccharides have a variety of fucose and sulphate decorations. Species capped with α-GalNAc were determined using exo-acting
enzymes specific to that sugar and linkage (see Supplementary Fig. 8).
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specific to either the α-GalNAc or α-galactose found on blood
group A or B structures, respectively, enabled identification of
these non-reducing end decorations on some GH16 products
(Supplementary Fig. 8). The use of endo- and exo-acting enzymes
in combination against different mucins could be a powerful tool
in exploring different structures in O-glycan research and
identification of disease biomarkers.
Investigating the specificity of the GH16 O-glycanases. A range
of defined oligosaccharides were used to further probe the spe-
cificity of the O-glycan active GH16 enzymes (Supplementary
Figs. 9–12). TriLacNAc represents the repeating unit of O-glycans
side chains and was hydrolysed at two of the Galβ1,4GlcNAc
linkages by the GH16 mucinases. The middle bond is the first to
be cleaved to produce two trisaccharides, one of these is then
hydrolysed further to produce GlcNAc and GlcNAcβ1,3Gal. This
order was determined by identifying the products using digestion
with specific exo-acting enzymes (Supplementary Fig. 9). The
activity against TriLacNAc revealed that all nine GH16 enzymes
are endo β1,4-galactosidases with a requirement for a β1,3-linked
sugar at the -2 position.
The GH16 mucinases were also tested against other defined
oligosaccharides to explore differences between the enzymes and
the importance of different subsites in substrate recognition
(Supplementary Figs. 10–12). In summary, for the positive
subsites, all displayed a preference for O-glycans over milk
oligosaccharides (which are built on a lactose core), indicating
that a GlcNAc is preferred at the +1 site rather than a Glc. In
terms of the negative subsites, blood group sugars in the -3’
(fucose) and -4 (GalNAc or Gal) subsites are tolerated in most
cases but reduce the rate of hydrolysis (Supplementary Table 4).
A summary of the specificities of the GH16 O-glycanases
described in this report is shown in Fig. 4.
Endo O-glycanase activity on the cell surface. To assess if there
is endo O-glycanase activity on the cell surface we used whole cell
assays (Fig. 5 and Supplementary Fig. 13). Bacterial cultures
grown on PGM III were harvested, washed and exposed to either
TriLacNAc or TetraLacNAc. The data revealed the same pattern
of degradation as that produced by the recombinant GH16 O-
glycanases against TriLacNAc. The identity of the products was
confirmed using diagnostic assays using exo-acting enzymes of
known specificity for two of the time points (Fig. 5b and Sup-
plementary Fig. 13). These data indicate that GH16 O-glycanase-
like activity is present on the surface of all four of the bacterial
species studied here.
Activity against polyLacNAc structures in non-mucin host
glycan. Keratan sulphate (KS) chains are anchored to the protein
through N-linkages, O-linkages and O-mannosylation are termed
KS-I, KS-II and KS-III, respectively30 (Supplementary Fig. 4).
Examples of areas of the body enriched in KS-I, KS-II and KS-III
include the cornea, skeletal and brain, respectively30. Keratan
sulphate is present in the GI tract from sloughed off epithelial
cells and also dietary sources.
Keratan sulphate has a similar structure to O-glycans and is
also composed of a repeating polyLacNAc structure with 6 S
sulfation possible on both the galactose and GlcNAc, but with less
fucosylation and sialylation than most mucins. The nine GH16
O-glycanases were found to be active against both egg and bovine
corneal keratan sulphate and the released products indicate that a
significant number of sulphate groups can be tolerated by the
enzymes (Supplementary Fig. 14). Degradation of KS also
supports the previous finding that fucose decorations are not
required for activity of the GH16 O-glycanases. Activity against
this KS substrate also demonstrates that the O-glycanases target
polyLacNAc chains in a range of glycans, likely including keratan
sulphate in the gut, although we could not test growth on KS as
the glycan was only available in small amounts.
Activity of the GH16 O-glycanases against classical GH16
substrates. The activity of GH16 enzymes against host glycans is
unusual in comparison to the specificities displayed for previously
characterised members of the family. The activities of the GH16
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Fig. 4 Heat map showing the activity of the GH16 O-glycanases against different oligosaccharides. The data summarises the specificity of the GH16 O-
glycanases described in this report. From left to right the glycans are TetraLacNAc, TriLacNAc, paraLacto-N-neohexaose, Lacto-N-neotetraose, Lacto-N-
tetraose, Lacto-N-triose, Galβ1,3GalNAc β1,3Galβ1,4Glc tetrasaccharide Blood group A hexasaccharide, Blood group B hexasaccharide, Blood group H
pentasaccharide, LacNAc, Blood group H tetrasaccharide II, 3-sialyllactose and P1 antigen. The linkages are β unless otherwise labelled and the bonds
cleaved are indicated by the black arrows. Partial and trace activity are the estimation of greater than or less than 50% degradation, respectively, under the
assay conditions used. A more detailed summary can be found in Supplementary Table 4. The predicted cellular locations of each enzyme is indicated on
the far right of each row.
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O-glycanases were tested against polysaccharides previously
shown to be substrates for GH16 family members to assess their
level of O-glycan specificity (Supplementary Fig. 15). No activity
could be detected for any of the enzymes against agarose, κ-
carrageenan, porphyran, pectic galactan, xyloglucan or chitin.
However, Amuc_0724 displayed significant endo-like activity
against laminarin and weak activity against barley β-glucan and
lichenan. BF4060, BACCAC_02680 and BACCAC_03717 also
displayed some very weak activity against laminarin. The possible
rationale for the activity of Amuc_0724 against Glc configured
substrates is discussed below. Other non-mucin host poly-
saccharides are also present in significant amounts in mucosal
surfaces, including chondroitin sulphate (CS), heparin (Hep) and
hyaluronic acid (HA). The O-glycan active GH16 enzymes were
also tested against these polysaccharides and no significant
activity could be found, except for a small amount of low mole-
cular weight product released from Hep (Supplementary Fig. 15).
Overall these data reveal that the nine GH16 enzymes analysed
are endo acting β1,4-galactosidases that display a preference for
polyLacNAc structures found in mucins and other similar glycans
such as KS.
Crystal structures of O-glycan active GH16 family members.
To investigate the structural basis for O-glycan specificity dis-
played by the GH16 O-glycanases we attempted to obtain crystal
structures of these enzymes in complex with substrate. Crystal
trials were set up with both wild-type protein and mutants of the
catalytic nucleophile. We also co-crystallised the different pro-
teins with TriLacNAc to obtain substrate or product complexes
where possible. Six separate data sets were collected from four of
the enzymes. The apo structures of BACCAC_02680, BACCA-
C_02680E143Q, BACCAC_03717 and Amuc_0724 were obtained
to 2.0, 2.1, 2.1 and 2.7 Å, respectively. Structures of BF4060 and
BACCAC_02680E143Q were also obtained with the Galβ1,4Glc-
NAcβ1,3 Gal product present in the negative subsites (despite the
latter enzyme being a catalytic mutant; Supplementary Fig. 16) to
3.3 and 2.0 Å (Fig. 6, Supplementary Tables 5–7, and Supple-
mentary Figs. 16–20). The electron density of the trisaccharide
product allowed us to model in the sugars, the conformations
were checked using Privateer, and these conformations correlated
with what had been seen previously in other GH16 structures
(Supplementary Fig. 17 and Supplementary Table 7)31,32.
All of the GH16 enzymes comprise a β-jellyroll fold,
characteristic of the family, consisting of two β-sheets composed
of β-strands that form the core fold, which were superimposable
with other GH16 structures previously published. A cleft running
along the concave surface of the enzymes contains the active site
and where the trisaccharide product was bound in the cases of
BF4060 and BACCAC_02680E143Q (Fig. 6a). While the location
of the substrate binding site is conserved in the GH16 family, the
structures of these clefts vary depending on substrate specificity
(Supplementary Fig. 18a). Some form a tight tunnel for linear
undecorated glycans (e.g., agarase from Zobellia galactanivor-
ans33), others are much more open to accommodate decorations
(e.g., xyloglucanase from Tropaeolum majus34), while some
GH16 enzymes have substrate binding clefts that are curved to
optimise binding to highly curved glycans such as laminarin35.
There is also a single example of a GH16 family member that has
evolved a pocket-like active site to recognise and cleave a specific
disaccharide from the terminus of glycan chains in gastric
mucin36 (Supplementary Fig. 18b). The key structural features
that modulate the shape of different clefts are the surrounding
loops and short α-helices extending from the β-strands of
the core fold (exemplified in Supplementary Fig. 19). These
extensions have been likened to fingers that interact with
substrate, thereby dictating specificity, and that nomenclature is
used herein37. BF4060 and BACCAC_02680E143Q have four
fingers and BACCAC_03717 and Amuc_0724 have five out of six
possible fingers that have been observed previously in other
GH16 structures37.
Inspection of the BACCAC_02680E143Q and BF4060 structures
with product reveal most of the interactions between enzyme
and sugar are with the Gal at −1 and GlcNAc at −2. The
−1 subsite in BACCAC_02680E143Q is composed of a number
of aromatics, which are also a common feature of the
GH16 structures available (Fig. 6b). This enzyme possesses four
fingers (numbers 1, 3, 5 and 6) that extend towards the cleft, with
fingers 1 and 3 sandwiching the negative subsites and fingers 5
and 6 sandwiching the positive subsites. Finger 3 contains the
sequence motif for GH16 subfamily 3, which consists of three
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Fig. 5 Surface activity of mucin-grown A. muciniphila against TriLacNAc. a A. muciniphila cells were grown on PGM III, harvested and TriLacNAc added to
assess surface enzyme activity. Samples were analysed at different time points following addition of TriLacNAc. Equivalent data for the Bacteroides species
are shown in Supplementary Fig. 13. b Samples from two different time points of the A. muciniphila whole cell assay were incubated with two different exo-
acting enzymes of known specificity to identify the products. The asterisks indicate the time points analysed. The top and bottom of the glycan structures
shown is the non-reducing and reducing end, respectively. A: original sample, B: +β1,4-galactosidase BT0461GH2, C: +broad-acting β-GlcNAc’ase
BT0459GH20. For example, in both time points, the two different types of trisaccharides can be seen to be hydrolysed in the separate digests: (1)
Galβ1,4GlcNAcβ1,3Gal disappears in ‘B’ and products Gal and GlcNAcβ1,3Gal are now present, (2) GlcNAcβ1,3Galβ1,4GlcNAc disappears in ‘C’ and
products GlcNAc and Galβ1,4GlcNAc are now present. These experiments were carried out once, but multiple pilot experiments were run and were
consistent with the data shown. The source data are provided in the source data file.
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tryptophans interspaced by other residues28. BF4060 and
BACCAC_02680 display 79% identity and unsurprisingly the
structures of these two enzymes are almost identical in the cleft
region. In contrast, BACCAC_03717 and Amuc_0724 both
possess a finger 2 (in addition to 1, 3, 5 and 6) and this has a
more variable topology than the other fingers (Fig. 6a). For
Amuc_0724, finger 2 sits over the top of finger 1, but in the
BACCAC_03717 structure it points away from the cleft. This
could reflect the flexibility of finger 2 in this enzyme and could
potentially come down over loop 1 in solution like in the
Amuc_0724 structure. The B-factor putty projections of the
GH16 crystal structures show finger 2 is dynamic in the
BACCAC_03717 (Supplementary Fig. 19) and alternative
conformations of individual fingers from of other GH16 family
members has been observed previously, a finding which is
indicative of flexibility38.
Structural basis for specificity of the GH16 O-glycanases. Pre-
viously characterised GH16 family enzymes target a variety of β-
glucan and galactan substrates (Supplementary Fig. 4). Glucose
and galactose differ only in the hydroxyl group at C4 being
equatorial or axial, respectively. Anhydrogalactose is also present
in agarose and carrageenan and sulfation in porphyran and car-
rageenan (Fig. 6e). Porphyran and carrageenan are 6 S and 4 S
sulfated, respectively, and these decorations would therefore point
into the GH16 binding cleft at subsites −2 and −1, respectively.
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Structural features characteristic to O-glycans include alternating
Glc and Gal configured sugars and additionally the presence of
GlcNAc, which is not found in other GH16 substrates (Fig. 6e).
Furthermore, 6 S is found on both Gal and GlcNAc and 3 S is
possible on the galactose at the non-reducing ends of O-glycan
chains.
The new GH16 structures reported here were systematically
compared to the GH16 structures available for glucanases,
laminarinases, porphyranases, carrageenases, xyloglucanases and
other activities. Each subsite was analysed in comparison to the
structures of GH16 enzymes with other specificities to understand
the structural basis for O-glycan specificity. This detailed analysis
highlighted four structural features of the mucin active GH16
family members that tailor these enzymes towards O-glycans.
Firstly, in the −1 subsites of the structures from Bacteroides
spp., the closed space around the O4 hydroxyl explains why only
Gal configured sugars can be recognised as the equatorial O4 of
glucose would not be accommodated (Fig. 6c). The structure of
Amuc_0724 in this area is much more open and is a likely
explanation for this enzymes additional activity against laminarin
(Supplementary Fig. 15). Furthermore, the open space at the O4
in Amuc_0724 is a potential pocket for sulfation that the
Bacteroides spp. enzymes would not be able to accommodate
(Supplementary Fig. 20). Phylogenetic analysis reveals the mucin
active GH16 enzymes are likely to have derived from β-
glucanases rather than β-galactanases (Supplementary Fig. 5),
however in the −1 subsite the selection is for galactose rather
than glucose. This finding indicates the enzymes have evolved
specificity for O-glycan structures from a β-glucanases ancestor
(s). For the GH16 family as a whole, there is no conserved way of
selecting between glucose and galactose and specificity for
galactans arises in distinct branches of β-glucanases of the
phylogenetic tree (Supplementary Fig. 5, the endo-β1,3-galacta-
nases are another example of this), providing an example of
convergent evolution. These finding suggest that the side activity
seen in Amuc_0724 for some substrates with glucose in the
−1 subsite is likely a relic of its evolutionary origin.
The second structural feature characteristic (but not unique) to
O-glycanases is the requirement for accommodation of a β1,3-
linkage between the −1 and −2 sugars. The structural features
driving this specificity in the O-glycan active GH16 enzymes are
identical to those in the GH16 enzymes specific for mixed linkage
β-glucan39. An aromatic residue in the −2 subsite (also a part of
the sequence motif from the subfamily) acts as a hydrophobic
platform for the GlcNAc at this position and is at 90° relative to
an aromatic residue carrying out the same function in the −1. For
example, BACCAC_02680 residues W131 and W138 are plat-
forms for the −1 and −2 sugars, respectively (Fig. 6b). This
feature is conserved amongst β-glucanases (not in GH16 enzymes
with other activities) and is also required also for the degradation
of polyLacNAc-based glycans.
Thirdly, in the O-glycanases, at the −2 subsite where the
GlcNAc is accommodated, the N-acetyl group of the sugar faces
away from the cleft and towards the solvent. Other non-mucinase
GH16 enzymes with tighter clefts would not be able to
accommodate this structure (for example see PDB 6JH5 and
4CTE). An additional observation about the −2 subsite and
accommodation of sulphate groups resulted from the overlay of a
porphyran product (originally from a porphyranase
GH16 structure40) into the clefts of the O-glycanase GH16
enzymes. This indicates that sulfation on the GlcNAc at C3 could
be accommodated within the cleft at the −2 subsite (Supple-
mentary Fig. 20f).
The fourth structural feature likely driving O-glycan specificity
concerns the +1 subsites. The substrate depletion assays support
a preference for GlcNAc in the +1 subsite as the rate of
degradation of TriLacNAc is much faster than that of milk
oligosaccharides (Supplementary Fig. 10). Although the product
complexes reported here do not have sugars in the positive
subsites, comparison with previously published GH16-substrate
complexes could be used explore how GlcNAc would sit in the +
1 subsite and propose a structural rationale for the preference of
GlcNAc at this position in the mucin active enzymes (Fig. 6d).
BF4060 (and also its close homologue BACCAC_02680) has a
significant preference for TriLacNAc over milk oligosaccharides
(Supplementary Fig. 10) and analysis of the +1 subsite shows a
narrow slot where a GlcNAc would insert with the N-acetyl
pointing away from the cleft and S174 from Finger 5 would
pincer the N-acetyl against finger 6, thus generating specificity for
GlcNAc over glucose (Fig. 6d). The structures for BAC-
CAC_03717 and Amuc_0724 are more accommodating of milk
oligosaccharides and have more open +1 subsites.
Overall these data provide significant insight into the structural
features that drive the polyLacNAc specificity of the GH16 O-
glycan active enzymes characterised here.
Generating O-glycan profiles from human tissue samples. O-
linked glycans are common modifications to proteins and lipids
in addition to being the major component of mucins. Changes in
O-glycosylation patterns in mucins and other glycoproteins have
previously been detected in a variety of disease states and these
changes can contribute to disease progression and severity, for
example, by facilitating the metastasis of cancer. Therefore, these
alterations represent promising biomarkers for the screening and
prognosis of different diseases, especially in combination with
other exo-acting enzymes of known specificity with activity
against O-glycans. Indeed, sialyl Lewis X, sialyl lewis A and
Fig. 6 Structures of four of the O-glycan active GH16 family members characterised in this study. a Crystal structures of BACCAC_02680E143Q,
BF4060, BACCAC_03717, and Amuc_0724. The loops extending from the active site that are proposed to be involved in substrate specificity in GH16
enzymes are termed ‘fingers’ and are colour coded. b Subsites −1 to −3 of BACCAC_02680E143Q and BF4060 have the product of TriLacNAc cleavage
bound (Galβ1,4GlcNAcβ1,3 Gal; shown in symbol form next to the structures with the sugar in each subsite labelled). The residues interacting directly with
sugar are shown as sticks. The aromatic residues shared with β-glucanase GH16 family members that drive specificity for a β1,3 between the −1 and
−2 sugars are shown (W129, W138 and W131, W140; See Supplementary Fig. 20 for active sites of BACCAC_03717, and Amuc_0724). c A surface
representation of the regions surrounding the −1 subsite showing the selection for the axial O4 of Gal in the three Bacteroides enzymes, while Amuc_0724
has a more open ‘tunnel’ like space that appears to also allow accommodation of the equatorial O4 of Glc. The product from BACCAC_02680E143Q was
overlaid in the BACCAC_03717, and Amuc_0724 structures. Colours represent the different ‘fingers’. d A view of the predicted +1 subsite of BF4060 and
BACCAC_03717 overlaid with the glucose from the +1 subsite of a laminarinase from Phaenerochaete chrysosporium. The +1 subsites are much more closed
for BF4060 and BACCAC_02680E143Q compared to BACCAC_03717, and Amuc_0724. e, An overview of the monosaccharides occupying the different
subsites in GH16 family members with different activities. Linkages also shown. It should be noted that the sulfation will be variable along the O-glycan
chain and there will also be fucose decorations. This situation is similar to porphyran, where the polysaccharide can have a variable composition, but the
subsite occupancy shown here reflects the observations of structures of enzyme-glycan complexes currently available for porphyranases.
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Forssman antigens are already used as biomarkers for different
types of cancers41–43.
To demonstrate that the GH16 enzymes could be used to
generate O-glycan profiles for such screening purposes, we
analysed the activity of one of the O-glycanases against mucins
from three different types of human tissue/cells. Tissues from two
adults suffering from ulcerative colitis (UC) were obtained as well
as samples from preterm infants with necrotising enterocolitis
(NEC); 4 infants of gestations 26, 27, 28 and 35 weeks. The mucus
layer was scraped from the small amount of tissue (approximately
1 cm2) that could be spared by the pathologist and we used this to
carry out assays. We also tested mucins produced by a number of
cultured colorectal cancer (CRC) cell lines originating from
different patients.
The human mucin samples were incubated with Amuc_0724,
due to its broad activity, in combination with the sialidase
BT0455GH33 and the products were labelled with procainamide,
and analysed using LC-FLD-ESI-MS. The data reveal that
Amuc_0724 was able to release a range of Gal terminated and
variably fucosylated and sulfated oligosaccharides from all of the
samples tested, with similar structures to those identified from
porcine SI mucin (Fig. 7 and Supplementary Fig. 21).
Whilst the presence of particular oligosaccharides in diseased
vs healthy tissue was not assessed in these proof-of-principle
experiments, the glycan profiles obtained demonstrate the
potential of using these enzymes for either precision medicine
or basic research applications using very small amounts of tissue.
A total of 22 different oligosaccharides were detected in the
various samples analysed and the glycan profiles observed varied
significantly between samples (Fig. 7 and Supplementary Fig. 21).
Furthermore, multiple peaks have the same sugar composition,
indicating the different peaks are due to variation in linkages
between the sugars and that these can be differentiated using this
approach (e.g. Fig. 7a, glycan 2). The variation in glycan profiles
observed using the O-glycanase digestion suggest that these
enzymes could be promising tools to discover disease-specific
biomarkers.
Discussion
Here we describe the characterisation of members of the GH16
family that have a specificity for the Galβ1,4GlcNAc linkage in
the polyLacNAc chains found in mucins and other O-glycans.
This discovery of endo-acting O-glycanases expressed by pro-
minent mucin degrading gut bacteria is an important step for-
ward in furthering our understanding of the complex relationship
between the HGM and host.
We observed activity of these O-glycanases on both animal and
human mucins from a range of tissues including the stomach and
the small and large intestine. While much of the O-glycan that
colonic microbiota will be exposed to will be from MUC244, as
the major mucin expressed in the distal intestine, it is worth
noting that these bacteria will also come into contact with sig-
nificant amounts of MUC5AC, MUC5B and MUC6 mucins that
have moved down the digestive tract from the saliva, oesophagus
and stomach where they originated. In addition to these gel-
forming mucins, gut microbes will be exposed to membrane-
associated mucins that are a part of the apical surface glycocalyx
of epithelial cells, especially when dead cells are sloughed off the
epithelium throughout the GI tract and these include MUC3,
MUC12 and MUC1745,46. Furthermore, greater than 80% of
secreted proteins are O-glycosylated and the gut microbiota will
come into contact with these from both host and dietary
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Fig. 7 Examples of the O-glycan profiles that can be produced from a variety different human mucins by the Amuc_0724 O-glycanase. Mucins from
different samples were pre-treated with the broad acting sialidase BT0455GH33 and then digested with the GH16 and products analysed by LC-FLD-ESI-
MS. a Inflamed colonic tissue removed during a laproascopic panproctocolectomy from a patient with UC. b Bowel tissue from neonates with necrotising
enterocolitis. c Colorectal cancer cell lines. Small amounts of Neu5Gc are seen in some of the UC samples (e.g., panel a) suggesting either the presence of
contaminating dietary animal O-glycans remaining in the mucus layer or that this xenobiotic sugar has been incorporated into human mucins from dietary
sources. The O-glycan profiles of all the different samples analysed are shown in Supplementary Fig. 21.
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sources47. The activity of the GH16 enzymes against the broad
range of substrates reported here indicate that these microbes can
access O-glycans from the different types of mucins moving
through the GI tract.
The discovery of this endo O-glycanase activity is in contrast to
the previously proposed ‘exo-trimming’ model of mucin degra-
dation and is more similar to pathways for degradation of other
glycans seen in Bacteroides spp18,48. In all of the Bacteroides
species studied here, at least one of the GH16 endo-mucinases is
predicted to be a lipoprotein and whole cell assays support GH16
O-glycanases being localised to the cell surface. On the cell sur-
face, the endo-mucinase and sialidase activities are likely the
initial steps in O-glycan breakdown and other exo-acting
CAZymes that trim capping sugars are also likely present
(Fig. 8). The oligosaccharide products are then imported via outer
membrane SusCD apparatus for further degradation in the
periplasm. Several of the GH16 O-glycanases identified here are
predicted to be periplasmic rather than cell surface. The role of
these enzymes in the periplasm is likely to increase the efficiency
of breakdown of the imported mucin oligosaccharides by
increasing the number of chain ends available to periplasmic exo-
acting glycosidases, a feature observed previously in glycan
breakdown pathways48.
Although targeting of polyLacNAc structures by the GH16
enzymes is likely an initial step in mucin breakdown, further
processing of the remaining mucin would be required. The
polyLacNAc side chains are attached to different core glycan
structures, which are in turn linked to the peptide backbone. This
is most likely dealt with through a combination of extracellular or
surface exo-acting glycosidases and peptidases. Indeed, it has
recently been shown that gut microbes, including B. thetaiotao-
micron, express glyco-peptidases that specifically target polypep-
tides with O-glycan core structures still attached49,50.
While this model applies to Bacteroides spp, it is currently
unknown how A. muciniphila cells access complex glycans6.
However, there is direct experimental evidence that at least one of
the GH16 mucinases expressed by A. muciniphila (Amuc_2108)
is localised to the outer membrane during growth on mucin, and
A. muciniphila cells also display O-glycanase-like activity on the
cell surface, supporting a similar role for these enzymes in initi-
ating mucin breakdown.
Structures of several O-glycanase enzymes revealed the char-
acteristics of the subsites driving the specificity towards poly-
LacNAc chains. In particular, alternating Gal and GlcNAc sugars,
a requirement for a β1,3 linkage between the −2 and −1 subsites,
and potential pockets for sulfation or fucosylation. There is a
relatively low number of required subsites for catalysis, in con-
trast to that seen for GH16 enzymes with other activities, likely
reflecting the highly heterogeneous nature of mucin O-glycans.
The combination of these new GH16 endo O-glycanase
activities with other exo-acting CAZymes and the sensitive ana-
lytical techniques applied to human mucin samples described
here demonstrates potential applications in both fundamental
research and medicine. We hope this study facilitates partner-
ships between basic researchers and clinicians to explore the
structures of O-glycans in a range of diseases on a larger scale in
order to develop more effective biomarkers (e.g. for earlier
detection of disease). This could lead to less invasive and more
rapid techniques for diagnosis and monitoring remission in
prevalent diseases like the ones explored here.
Overall, the findings reported here contribute significantly
towards our understanding of the molecular mechanisms of
mucin breakdown by the microbiota, a key process in main-
taining the host-microbe symbiosis in the gut. These findings also
open up the exciting possibility of exploiting this activity for
characterisation and detection of biomarkers to allow more
effective and earlier diagnosis of intestinal diseases such as IBD
and CRC.
Methods
Sources of glycans and glycoproteins. TriLacNAc was purchased from Elicityl
and the rest of the defined oligosaccharides were from Carbosynth. PGM II and III
(Sigma) was produced by dissolving in DI water at 50 mgml−1 and the precipitate
removed by centrifugation before assays were carried out (leaving 35–40 mgml−1).
Porcine small intestinal mucin was prepared as previously described with the only
modification being a double CsCl gradient without Sepharose separation or SDS-
PAGE in between51. Keratan was prepared as described previously52.
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Bacterial strains. The Bacteroides strains used were: B. thetaiotaomicron VPI-
5482, B. fragilis NCTC9343, B. caccae ATCC43185, B. cellulosilyticus DSM14838, B.
finegoldii DSM17565, B. vulgatus ATCC8483, B. ovatus ATCC8482, B. intestinalis
DSM17393, and Akkermansia muciniphila ATCC BAA835/DSM22959.
Cloning, expression and purification of recombinant proteins. The DNA
encoding the enzymes described in this report were amplified from genomic DNA
and cloned into pET28b (Novagen) excluding the signal sequences, which were
identified using SignalP 5.053. Site-directed mutagenesis was carried out using
Quikchange kit (Agilent). All recombinant enzymes were expressed in TUNER
(Novagen) E. coli cells cultured in LB broth with kanamycin (50 μg ml−1) at 37 °C
in an orbital shaking incubator at 180 rpm. Cells were growth to mid-exponential
phase (OD600 ~0.6), cooled to 16 °C, 0.2 mM of isopropyl β-D-
thiogalactopyranoside (IPTG) and incubated overnight at 16 °C in an orbital
shaking incubator at 150 rpm. Cells were harvested, lysed by sonication, and the
His-tagged protein was purified from the lysate by immobilised metal ion affinity
chromatography using Talon resin (Clontech). The protein was bound to the resin,
washed, and increasing amounts of imidazole used to elute the recombinant
protein.
Crystallisation. For crystallography studies, the enzymes were purified using a
further size exclusion chromatography step using a HiLoad Superdex 200 pg on an
AKTA Pure FPLC system (GE Healthcare Life Sciences). SDS-PAGE gels were used
to determine the pure fractions, which were then pooled and concentrated.
The GH16 enzymes were initially screened using commercial kits (Molecular
Dimensions and Qiagen). Protein concentrations, crystallisation conditions and
cryo-protectant used are given in Supplementary Table 6. The drops, composed of
0.1 μl of reservoir solution plus 0.1 or 0.2 μl of protein solution, were set up in
sitting drop vapour diffusion plates by a Mosquito crystallisation robot (SPT
Labtech) and incubated at 20 °C. BACCAC_02680E143Q was incubated with 5 mM
of ligand for one hour and co-crystallised. BF4060 crystals were soaked in solution
containing cryo-protectant and 3.5 mM TriLacNAc for 5 minutes prior to flash
cooling in liquid nitrogen.
Data sets were integrated with XDS (Mar 2019)54 or DIALS 1.14.555 or XIA2
0.565356 and scaled with Aimless 0.7.457. Initial phases were obtained for
Amuc_0724 by molecular replacement with Molrep 11.6.0458 using 3WUT and
Phaser 2.8.259 using a GH16 laminarinase from Rhodothermus marinus as search
model (PDB 3ILN) for all the other proteins. Models were refined with refmac60
and manual model building with Coot 0.8.9.161. Final models were validated with
MolProbity62. Other software used were from CCP4 suite63 or Phenix suite
1.18.385564. Figures were made with Pymol65. Validation of the sugar models was
completed using Privateer MKIII32. The statistics from data processing and
refinement can be found in Supplementary Table 5 and Privateer results can be
found in Supplemental Table 7.
Growth of bacterial species. All growths were carried out in an anaerobic cabinet
(Whitley A35 Workstation; Don Whitley). Glycerol stocks of bacteria were revived
overnight in tryptone-yeast-extract-glycerol medium plus haematin66. A. mucini-
phila and B. xylanisolvans required chopped meat broth (CMB) at this stage
instead11,24. Monitoring growth against different substrates was done in minimal
media for all Bacteroides spp.8, however for A. muciniphila CMB was used without
the addition of monosaccharides. For plate growths, a 96-well plate was monitored
at 600 nm for 48 h by a Biotek Epoch plate reader. Growth against mono-
saccharides and PGM II and III (precipitate removed) was carried out at 35 and
40 mgml−1, respectively. Growth against heparan sulphate and chondroitin sul-
phate was carried out at 20 mgml−1 and hyaluronic acid at 10 mgml−1 for visc-
osity reasons. GraphPad Prism was used to produce the figures.
Recombinant enzyme assays. For overnight assays, defined oligosaccharides were
incubated at a final concentration of 1 mM in the presence of 3 μM of enzyme. For
substrate depletion assays, 1 mM oligosaccharides were incubated with 0.1 μM
enzyme and samples removed at various times. Some enzymes required increasing
to 1 μM to assess the activity against substrates. The concentrations of different
substrates are indicated to throughout the figures. All assays included 20 mM
MOPS, pH 7, and were carried out at 37 °C. GraphPad Prism was used to produce
the figures.
Whole cell assays to determine cell surface activity. 5 ml cultures (including
40 mgml−1 PGM type III) were grown on minimal media for Bacteroides species
and modified CMB for A. muciniphila. Cells were harvested at mid-exponential,
washed with PBS twice, and resuspended in 0.5 ml 2× PBS. Assays (200 μl) inclu-
ded 100 μl of cells, a final concentration of 1 mM Tri- or TetraLacNAc, and
were incubated at 37 °C. Aliquots were removed over time and boiled to stop the
reaction.
Thin-layer chromatography. For defined oligosaccharides and other poly-
saccharides, 3 μl of an assay containing 1 mM substrate was spotted on to silica
plates (Merck; TLC Silica gel 60 F254). For assays against mucin, this was increased
to 9 μl. The plates were resolved in running buffer containing butanol/acetic acid/
water (2:1:1) and stained using a diphenylamine-aniline-phosphoric acid stain67.
Colorectal cancer cell line growth. Human CRC cell lines were obtained from the
Department of Surgery of the Leiden University Medical Center (LUMC), Leiden,
The Netherlands. The cell lines cultured at the LUMC were kept in Hepes-buffered
RPMI 1640 culture medium containing L-glutamine and supplemented with
penicillin (5000 IU ml−1), streptomycin (5 mgml−1), and 10% (v/v) foetal calf
serum (FCS). Cells were incubated at 37 °C with 5% CO2 in humidified air. The
cells were harvested after reaching approximately 80% of confluence. To detach the
cells from the culture flask a trypsin/EDTA solution in 1× PBS was used. Enzyme
activity was stopped using the medium in a ratio 2:5 (trypsin:medium v/v). The
cells were counted using TC20 automated cell counter from Bio-Rad technologies
(California, USA) based on trypan blue staining. The cells were washed twice with
5 ml of 1× PBS, aliquoted to 2.0 × 106 cells ml−1 of 1x PBS and pelleted by cen-
trifuging 3 min at 1500g. Finally, the supernatant was removed, and the cell pellets
were stored at −20 °C. Two million cells were used per reaction.
Human sample collection. IBD tissue samples were from two subjects. Matched
ileal and colonic samples were obtained from one panproctocolectomy and one
ileocaecal resection. Samples were transferred on wet ice directly to the laboratory
for mechanical isolation of the mucus layer by gently scraping using a pipette tip.
For NEC samples, fresh tissue was collected from surgically resected specimens
when a clinically necessary procedure was taking part, stored briefly in sterile
phosphate buffered saline and transported to the laboratory on ice.
HPAEC-PAD. To analyse the substrate depletion assays, sugars were separated
using a CARBOPAC PA-100 anion exchange column with a CARBOPAC PA-100
guard. Flow was 1 ml min−1 and elution conditions were 0–10 min, 100 mM
NaOH; 10–35 min 100 mM NaOH with a 0–166 mM sodium acetate gradient. The
software was Chromeleon Chromatography Data System.
Procainamide labelling. Reducing ends of GH16 products were labelled by
reductive amination using a procainamide labelling kit containing sodium cya-
noborohydride as reductant (Ludger). Before and after labelling the O-glycan
samples were cleaned up using PBM plates and S-cartridges, respectively (Ludger).
LC-FLD-ESI-MS of procainamide labelled glycans. Procainamide-labelled sam-
ples were analysed by LC-FLD-ESI-MS. 25 μl of sample was injected to a Waters
ACQUITY UPLC Glycan BEH Amide column (2.1 × 150 mm, 1.7 μm particle size,
130 Å pore size) at 40 °C on a Dionex Ultimate 3000 UHPLC instrument with a
fluorescent detector (λex= 310 nm, λem= 370 nm) attached to a Bruker Amazon
Speed ETD. Mobile phase A was a 50 mM ammonium formate solution (pH 4.4)
and mobile phase B was neat acetonitrile. Analyte separation was accomplished by
gradients running at a flow rate of 0.4 ml min−1 from 85 to 57% mobile phase B
over 115 min and from 85 to 62% over 95 min for mucin and keratan samples,
respectively. The Amazon speed was operated in the positive sensitivity mode using
the following settings: source temperature, 180 °C; gas flow. 41 min−1; capillary
voltage, 4500 V; ICC target, 200,000; maximum accumulation time, 50.00 ms;
rolling average, 2; number of precursor ions selected, 3; scan mode, enhanced
resolution; mass range scanned, 400 to 1700. HyStar v3.2 was used for data col-
lection of chromatography and mass spectrometry. GraphPad Prism was used to
produce the figures.
Analysis of mass spectrometry data. Mass spectrometry of procainamide-
labelled glycans was analysed using Bruker Compass Data Analysis Software and
GlycoWorkbench68. Glycan compositions were elucidated on the basis of MS2
fragmentation and previously published data.
Bioinformatics. Putative signal sequences were identified using SignalP 5.053.
Sequence identities were determined using Clustal Omega using full sequences69.
The IMG database (https://img.jgi.doe.gov/) was used to analyse synteny between
different species70. The CAZy database (www.cazy.org) was used as the main
reference for CAZymes71. To determine the boundaries between different modules
in a protein Pfam72 and SMART73,74 were used.
Alignments and phylogenetic trees were completed in SeaView75. Sequences
were aligned in SeaView using Clustal. Gblocks were applied to: allow smaller final
blocks, allow gap positions within the final blocks, and allow less strict flanking
positions. Trees were built using PhyML with aLRT (SH-like) branch support,
model-given amino acid equilibrium frequencies, no invariable sites, optimised
across site rate variation and the best of NNI and SPR tree searching operations.
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Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this paper.
Data availability
The crystal structures are deposited in the Protein Data Bank under the accession
numbers 6T2N, 6T2O, 6T2P, 6T2Q, 6T2R and 6T2S. The other data that supports the
findings in this paper are available in the Source Data file or upon request from the
corresponding authors.
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